Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.9702
-0.0498 (-4.88%)
At close: Aug 13, 2025, 4:00 PM
0.9734
-0.0092 (-0.94%)
Pre-market: Aug 14, 2025, 8:47 AM EDT

Akari Therapeutics, Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
9.929.6611.3613.538.089.16
Upgrade
Research & Development
2.876.985.459.569.138.82
Upgrade
Operating Expenses
12.7916.6516.8123.0917.2117.98
Upgrade
Operating Income
-12.79-16.65-16.81-23.09-17.21-17.98
Upgrade
Interest Expense
-0.3-0.24----
Upgrade
Interest & Investment Income
00.010.080.050.010.01
Upgrade
Currency Exchange Gain (Loss)
-0.030.010.140.45-0.190.35
Upgrade
Other Non Operating Income (Expenses)
2.912.086.584.84-0.030.53
Upgrade
EBT Excluding Unusual Items
-10.21-14.8-10.01-17.75-17.42-17.08
Upgrade
Merger & Restructuring Charges
-2.06-5----
Upgrade
Pretax Income
-12.27-19.79-10.01-17.75-17.42-17.08
Upgrade
Net Income
-12.27-19.79-10.01-17.75-17.42-17.08
Upgrade
Net Income to Common
-12.27-19.79-10.01-17.75-17.42-17.08
Upgrade
Shares Outstanding (Basic)
23125322
Upgrade
Shares Outstanding (Diluted)
23125322
Upgrade
Shares Change (YoY)
235.61%144.03%56.79%45.46%35.87%72.53%
Upgrade
EPS (Basic)
-0.54-1.66-2.04-5.69-8.12-10.81
Upgrade
EPS (Diluted)
-0.54-1.66-2.04-5.69-8.12-20.00
Upgrade
Free Cash Flow
-9.02-12.55-16.43-21.5-18.85-16.95
Upgrade
Free Cash Flow Per Share
-0.40-1.05-3.36-6.89-8.78-10.73
Upgrade
EBITDA
-12.78-16.63-16.8-23.08-17.21-17.97
Upgrade
D&A For EBITDA
0.010.010000.01
Upgrade
EBIT
-12.79-16.65-16.81-23.09-17.21-17.98
Upgrade
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q